Physician profile
Brian W Morrison
NPI 1134412083
$4,383.09
in general payments reported to CMS, 2019-2025
12 companies · $3,067 in 2025
The $3,067 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.55 · 2020: $120 · 2022: $131 · 2023: $224 · 2024: $783 · 2025: $3,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,730 · Food and Beverage: $1,256 · Education: $72.00 · Travel and Lodging: $16.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,730.00 |
| Food and Beverage | $1,255.81 |
| Education | $72.00 |
| Travel and Lodging | $16.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $3,033.48 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $364.03 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $262.40 | 2024 | Sotyktu |
| Janssen Biotech, INC. | $168.24 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $149.92 | 2024 | |
| Ucb, INC. | $142.46 | 2022-2023 | |
| Medical Device Business Services, INC. | $120.48 | 2020 | |
| Amgen INC. | $49.47 | 2024 | Otezla |
| Abbvie INC. | $33.31 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.61 | 2023 | Siliq, Targretin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.58 | 2023 | Spevigo |
| Resmed Corp | $14.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.